Prognostic role of neutrophil to lymphocyte ratio in lung cancers: A meta-analysis including 7,054 patients

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 2731-2738

  Zhao, Qing Tao ^a   Yang, Yong ^b   Xu, Shun ^c   Zhang, Xiao Peng ^a   Wang, Hui En ^a   Zhang, Hua ^a   Wang, Zhi Kang ^a   Yuan, Zheng ^a   Duan, Guo Chen ^a  

^a HEBEI GENERAL HOSPITAL   (China)

^b Sujiatun Central Hospital   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Lung cancer; Meta analysis; NLR; Prognosis

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; LUNG CANCER; LUNG RESECTION; NEUTROPHIL LYMPHOCYTE RATIO; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; SMALL CELL LUNG CANCER;

EID: 84943139429     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S90875     Document Type: Article

References (47)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545.
4. Grange JM, Krone B, Mastrangelo G. Infection, inflammation and cancer. Int J Cancer. 2011;128(9):2240–2241.
5. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504–508.
6. de Visser KE, Coussens LM. The inflammatory tumor microenviron­ment and its impact on cancer development. Contrib Microbiol. 2006;13:118–137.
7. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7(6):513–520.
8. Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48(2): 202–208.
9. Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, Horgan PG, McMillan DC. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2013;109(1):24–28.
10. Oh BS, Jang JW, Kwon JH, et al. Prognostic value of C-reactive pro­tein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78.
11. Sharaiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recur­rence in esophageal cancer. Ann Surg Oncol. 2011;18(12):3362–3369.
12. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associ­ated with patient prognosis in advanced gastric cancer. Oncology. 2007;73(3–4):215–220.
13. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134(10):2403–2413.
14. Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic sig­nificance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:117.
15. Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One. 2014;9(3):e92079.
16. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognos­tic performance of inflammation-based prognostic indices in primary oper­able non-small cell lung cancer. Br J Cancer. 2014;110(8):1930–1935.
17. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158.
18. Parmar MK, Torri V, Stewart L. Extracting summary statistics to per­form meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.
19. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed July 10, 2014.
20. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
21. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463.
22. Cannon NA, Meyer J, Iyengar P, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radia­tion therapy for early-stage non-small-cell lung cancer. J Thorac Oncol. 2015;10(2):280–285.
23. Choi JE, Villarreal J, Lasala J, et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung can­cer surgery: a retrospective study. Cancer Med. 2015;4(6):825–833.
24. Kos FT, Hocazade C, Kos M, et al. Assessment of prognostic value of “neutrophil to lymphocyte ratio” and “prognostic nutritional index” as a sytemic inflammatory marker in non-small cell lung cancer. Asian Pac J Cancer Prev. 2015;16(9):3997–4002.
25. Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide in unresect­able stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015;26(6):1134–1142.
26. Zhang H, Zhang L, Zhu K, et al. Prognostic significance of combina­tion of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS One. 2015;10(5):e126496.
27. Go SI, Lee A, Lee US, et al. Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer. Lung Cancer. 2014;84(1):79–85.
28. Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111(3):452–460.
29. Kacan T, Babacan NA, Seker M, et al. Could the neutrophil to lympho­cyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev. 2014;15(5):2089–2094.
30. Lin GN, Peng JW, Liu PP, Liu DY, Xiao JJ, Chen XQ. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia Pac J Clin Oncol. Epub 2014 Oct 31.
31. Wang X, Jiang R, Li K. Prognostic significance of pretreatment labo­ratory parameters in combined small-cell lung cancer. Cell Biochem Biophys. 2014;69(3):633–640.
32. Zhang T, Jiang Y, Qu X, Shen H, Liu Q, Du J. Evaluation of preopera­tive hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. PLoS One. 2014;9(10):e111494.
33. Botta C, Barbieri V, Ciliberto D, et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther. 2013;14(6):469–475.
34. Forget P, Machiels JP, Coulie PG, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013;20(suppl 3):S650–S660.
35. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lympho­cyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013;62(3):471–479.
36. Yildirim M, Yildiz M, Duman E, Goktas S, Kaya V. Prognostic impor­tance of the nutritional status and systemic inflammatory response in non-small cell lung cancer. J BUON. 2013;18(3):728–732.
37. Kaya V, Yildirim M, Demirpence O, Yildiz M, Yalcin AY. Prognostic significance of basic laboratory methods in non- small-cell-lung cancer. Asian Pac J Cancer Prev. 2013;14(9):5473–5476.
38. Cedrés S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864–869.
39. Lee Y, Kim SH, Han JY, Kim HT, Yun T, Lee JS. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or stan­dard chemotherapy as first-line therapy. J Cancer Res Clin Oncol. 2012;138(12):2009–2016.
40. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425–428.
41. Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45(11):1950–1958.
42. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer. 2011;47(17):2633–2641.
43. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695–699.
44. Szkandera J, Gerger A, Liegl-Atzwanger B, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the pre­dictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135(2):362–370.
45. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflam­mation. Nature. 2008;454:436–444.
46. Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer. 2010;127(7203):768–779.
47. O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–2036.